BRAIN Biotech Secures European Patent for CRISPR-BMC Genome-Editing Technology

The European Patent Office has granted BRAIN Biotech a patent for its CRISPR-BMC nuclease, designated as a substance patent with number EP4301852 B1. This novel family of CRISPR nucleases, developed by the company and known as BMC® (BRAIN Metagenome Cas), demonstrates high activity in various prokaryotic and eukaryotic organisms. CRISPR-BMC generates efficient double-strand breaks in genomes at defined locations, enabling targeted modifications to alter organism properties.

The technology allows precise genome editing across a wide range of organisms, including bacteria, yeasts, fungi, plants, and mammalian cells. BRAIN Biotech specifically applies this technology to optimize microbial production strains such as E. coli, Bacillus, Pichia, and Aspergillus for manufacturing biomolecules like enzymes, proteins, and small molecules. The BMC® nuclease family represents another proprietary CRISPR system alongside the company’s BEC® nucleases, both emerging from the BRAINBioIncubator research environment.

The patent grant provides BRAIN Biotech with freedom to utilize this proprietary technology for internal research and customer projects while opening significant commercial application potential. The company has already licensed the technology to various companies and plans to expand licensing activities. Adriaan Moelker, CEO of BRAIN Biotech, stated that the patent protection strengthens their position in offering technology that makes microorganism-based manufacturing processes more cost-effective across diverse application areas.

Alexander Pelzer, Head of R&D at BRAIN Biotech Zwingenberg, emphasized that CRISPR-BMC accelerates development of production organisms and strain development for customers through its speed and precision. The company leverages decades of molecular biology and microbiology experience to ensure reliable technology establishment in various organisms. The patent took effect on March 18, 2026, in European Unitary Patent countries, Great Britain, and Switzerland, with pending applications in other key regions including the United States and Japan.

BRAIN Biotech operates as a leader in researching, developing, and producing specialty enzymes for food and life sciences industries while developing microbial production strains and bioprocesses. The company maintains fermentation facilities in the United Kingdom with additional production sites in continental Europe and the United States. For more information about the company’s activities, visit https://www.brain-biotech-group.com.

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is BRAIN Biotech Secures European Patent for CRISPR-BMC Genome-Editing Technology.

The post BRAIN Biotech Secures European Patent for CRISPR-BMC Genome-Editing Technology appeared first on citybuzz.